Abstract: The invention provides compounds of general formula (I) wherein R1, R2, R3, R4, A, Q, U, V, W, X, Y and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions.

Abstract: The invention provides compounds of general formula (I) wherein R1, R2, R3, R4, R5, X, Y, Z, m and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions.

Abstract: Angiotensin converting enzyme inhibitors have the formula Z(CH.sub.2).sub.n CHR.sub.1 COOCHR.sub.2 COOHin which Z is --SR.sub.3, --COCHR.sub.4 NHCOR.sub.5, ##STR1## or --NHCHR.sub.7 COOH, R.sub.4, R.sub.5, R.sub.6, and R.sub.7, which may be the same or different, are each phenyl or alkylphenyl C.sub.7-12,R.sub.4 is hydrogen, alkyl C.sub.1-6, NHR.sub.8 or (CH.sub.2).sub.p R.sub.9,R.sub.2 is (CH.sub.2).sub.m XR.sub.10, alkyl C.sub.1-6 optionally substituted by a saturated 5- or 6-membered carbocyclic or heterocyclic ring, alkylhalo C.sub.1-6, alkylcyano C.sub.1-6, or alkyl phenyl C.sub.7-12, the phenyl being optionally substituted by NO.sub.2 or NH.sub.2,X is O, S(O).sub.q, C.dbd.O or NR.sub.11, andR.sub.10 is alkyl C.sub.1-6, alkylhalo C.sub.1-6, alkoxy C.sub.1-6, alkoxy C.sub.1-6 substituted by halogen, alkanoyl C.sub.1-6, S(O).sub.r R.sub.12, NR.sub.13 R.sub.14, phenyl, alkylphenyl C.sub.

Abstract: There are described compounds of formula I, ##STR1## in which R.sub.1 represents benzofurazanyl, pyridyl or phenyl, the pyridyl or phenyl being substituted,--COOR.sub.2 and --COOR.sub.3 are various ester groups,one of R.sub.7 and R.sub.8 represents alkyl Cl to 6 and the other represents --CONR.sub.10 R.sub.11 ; --CSNH.sub.2 ; --C(.dbd.NH)SR.sub.9 ; --S(O).sub.m R.sub.9 ; phenyl optionally substituted by one or more of alkyl Cl to 6, halogen, alkoxy Cl to 6 or nitro; alkyl Cl to 6 substituted by halogen; or furanyl;m is 0 or 1R.sub.9 is alkyl Cl to 6, andR.sub.10 and R.sub.11 each independently represent hydrogen or alkyl Cl to 6, or together with the nitrogen atom to which they are attached form a 5 or 6 membered heterocyclic ring.There are also described processes for making the compounds, and pharmaceutical, e.g. calcium antagonist, formulations containing them.

Abstract: There are described compounds of formula I, ##STR1## in which R.sub.1 represents benzofurazanyl, pyridyl or phenyl, the pyridyl or phenyl being substituted by one or more of the groups halogen, nitro, --CN, --OR.sub.9, --S(O).sub.p R.sub.9, or alkyl C1 to 6 optionally substituted by halogen,p is 0, 1 or 2,R.sub.2 and R.sub.3, which may be the same or different, each represent hydrogen; alkyl C1 to 6 optionally substituted by one or more of the groups halogen, cyano, --XR.sub.4, --NR.sub.5 R.sub.6 or phenyl; cycloalkyl C3 to 8 optionally substituted by alkyl C1 to 6; a 4, 5 or 6 membered oxygen or nitrogen containing heterocyclic ring which is optionally substituted by alkyl C1 to 6 the alkyl in turn optionally being substituted by one or more phenyl groups;R.sub.5 and R.sub.6, which may be the same or different, each represent alkyl C1 to 6 optionally substituted by phenyl,Y and Z together form a bond, and additionally, when R.sub.

Abstract: Propanolamine derivatives of the formula: ##STR1## wherein R.sup.2 is CH.sub.3 SO or CH.sub.3 SO.sub.2 ;R.sup.3 is hydrogen, methyl or methoxy; orR.sup.2 and R.sup.3 are together --S(O).sub.m (CH.sub.2).sub.4 --when S is attached at R.sup.2 or --(CH.sub.2).sub.n S(O).sub.m -- when S is attached at R.sup.3 (where m=1 or 2 and n=3 or 4);R.sup.4 is hydrogen or alkyl C.sub.1-4 ;Z is --(CH.sub.2).sub.2 -- or ##STR2## and their non-toxic salts. Processes for the preparation and pharmaceutical compositions thereof. The compounds exhibit both .beta.-adrenoreceptor antagonist activity and vasodilator activity and are indicated for use in the treatment of hypertension.

Abstract: Compounds are provided of the formula (II): ##STR1## wherein R.sub.1 is a group such that CO.sub.2 R.sub.1 is an ester group and A.sub.1 is a hydrogen atom or a methyl group. These compounds possess antibacterial activity. The preparation of these compounds is described.

Abstract: The compounds of the formula (II): ##STR1## and salts and esters thereof wherein R.sub.1 is a pyrimidyl group, or a pyrimidyl group substituted by one or two lower alkyl groups, or by a lower alkoxy group or by a lower acyloxy group; and R.sub.2 is a hydrogen atom or a group CR.sub.3 R.sub.4 R.sub.5 wherein R.sub.3 is a hydrogen atom or a hydroxy group; R.sub.4 is a hydrogen atom or a lower alkyl group; and R.sub.5 is a hydrogen atom or a lower alkyl group, a benzyl group, a phenyl group or is joined to R.sub.4 to form part of a C.sub.5-7 carbocyclic ring, have been found to be anti-bacterial-agents. Their preparation and use is described.

Abstract: The present invention relates to sodium, thallium, silver or lithium salts of the compoundHS--CH=CHNHC(O).sub.n R.sub.6wherein n is 1 or 2, R.sub.6 is alkyl, phenyl or substituted phenyl. The salts are useful as reagents for the preparation of sulfur containing Clavulanic acid derivatives.

Abstract: The compounds of the formula (II): ##STR1## and salts and esters thereof wherein R.sub.1 is a pyridyl group optionally substituted by one of two lower alkyl groups or lower acyloxy group, have been found to be antibacterial-agents. Their preparation and use is described.

Abstract: The present invention provides the antibacterial agents of the formula (II): ##STR1## wherein R.sub.1 is a group such that CO.sub.2 R.sub.1 is a carboxylic acid group or a salt thereof or is a group of the formula CO.sub.2 R.sub.1.sup.1 wherein R.sub.1.sup.1 is a group such that CO.sub.2 R.sub.1.sup.1 is an ester group, R.sub.2 is a hydrogen atom or a lower alkyl group; R.sub.3 is a hydrogen atom or a lower alkyl group; and R.sub.4 is a NH. CO.sub.n R.sub.6 group where R.sub.6 is a lower alkyl group, a phenyl group or a phenyl group substituted by one or two halogen atoms, lower alkyl or lower alkoxyl groups; and n is 1 or 2.A process for their preparation and their use in pharmaceutical compositions is also described.